Skip to main content
DrugPrice

Myrbetriq

Mirabegron

Generic availableProstate/Urologyby Astellas
$180.00
avg cost per claim
+6.4% year-over-year
$876.0M
Medicare Spending
4,860,000
Total Claims
580,000
Beneficiaries
$1,510.00
Annual Cost/Patient

Why Myrbetriq Costs $180.00 Per Claim

Myrbetriq (Mirabegron) is used to treat prostate/urology. According to CMS Medicare Part D spending data, the program spent $876.0M on this drug, covering 580,000 beneficiaries across 4,860,000 claims.

A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Mirabegron or talk to their doctor about therapeutic alternatives that may cost less.

Price Breakdown

Avg cost per claim (30-day)$180.00
Avg annual cost per patient$1,510.00
Total Medicare spending$876.0M
Total claims4,860,000
Beneficiaries580,000

Drug Details

Brand Name
Myrbetriq
Generic Name
Mirabegron
Active Ingredient
Mirabegron
Manufacturer
Astellas
Dosage Form
N/A
Route
N/A
Condition
Prostate/Urology
FDA Application
BLA125057

Frequently Asked Questions

Myrbetriq (Mirabegron) costs an average of $180.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $1,510.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.

Yes, a generic version of Myrbetriq (Mirabegron) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Mirabegron.

Medicare Part D spent $876.0M on Myrbetriq, covering 580,000 beneficiaries across 4,860,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.

Ask your pharmacist about generic Mirabegron, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.